Clinical Trials
5
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
2
40.0%
Not yet recruiting
2
40.0%
Recruiting
1
20.0%
No approval data available
- The ORBITA-CTO trial represents the first randomized, placebo-controlled study demonstrating that angioplasty significantly improves angina symptoms in patients with chronic total coronary occlusions. - Patients who received angioplasty were four times more likely to have improved angina scores and experienced 31 more angina-free days compared to those receiving a sham procedure. - The study enrolled 50 carefully selected patients with single-vessel chronic total occlusions and used extraordinary blinding measures to eliminate placebo effects. - Results provide robust evidence supporting symptom-driven PCI for chronic total occlusions when performed by experienced operators in specialized centers.
- Medera Inc. announced the appointment of three senior executives to strengthen its leadership team as the company advances its cardiac gene therapy programs through ongoing clinical trials. - The new appointments include Fubao Wang, Ph.D., as Chief Regulatory Officer and Chief Technical Officer at Sardocor, bringing over 28 years of pharmaceutical and biotech experience across gene therapy and regulatory affairs. - James Kim joins as Chief Corporate Officer with over 20 years of biopharmaceutical industry experience, having executed over 100 transactions totaling approximately $25 billion in financings and M&A deals. - Niharika Kamat, M.S., was appointed Vice President of Clinical Operations at Sardocor, bringing nearly 20 years of experience in global Phase 1-3 trials across cardiovascular and rare disease indications.
• Large-bore mechanical thrombectomy demonstrates superiority over catheter-directed thrombolysis in acute intermediate-risk pulmonary embolism, reducing clinical deterioration and ICU stays. • Percutaneous transmural arterial bypass shows sustained patency at 3 years for complex superficial femoropopliteal lesions, offering a bypass alternative without open surgery. • The FDA approved a bioresorbable scaffold for below-the-knee infrapopliteal disease, showing safety and efficacy at 1 year compared to angioplasty alone.
- The OCCUPI trial demonstrated that optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) is superior to angiography-guided PCI for cardiovascular outcomes in complex coronary lesions. - At 12 months, OCT-guided PCI significantly reduced major adverse cardiac events (MACE), driven primarily by a reduction in ischemia-driven target lesion revascularization (ID-TLR). - While OCT-guided PCI improved outcomes, it was associated with greater contrast volume use and longer procedural duration compared to angiography-guided PCI.
